REVB READ THE FULL REVB RESEARCH REPORT Revelation Biosciences (NASDAQ:REVB) announced that the FDA has accepted the company’s IND application for Gemini. This announcement allows the Company to ...

Specifically, Archroma will highlight its revolutionary DENIM HALO pretreatment and dyeing process for laser-friendly, easily ...

Purple Biotech's Phase 2 trial of CM24 in metastatic PDAC patients showed improved survival rates, biomarker responses, and ...

Final data demonstrate CM24 in combination with nivolumab and Nal-IRI/5FU/LV chemotherapy clear and consistent improvement ...

Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the treatment of ...

To continue reading this article you need to be logged in. Register for free or log in here.

This valuable study proposes a novel rapid-entry mechanism of S. aureus that involves the rapid release of calcium from lysosomes. The strength of the paper lies in a very interesting hypothesis; what ...

The Hermiston City Council unanimously passed an ordinance that requires businesses to install grease traps to pour out fats, ...

Metso is extending its hydrometallurgy offering with the launch of OKTOP® BIOX® Reactor. The reactor is ideal for the ...

The ASX opened higher after ceasefire news, while Bitcoin dipped below $92,000, and Web Travel surged, with Lynas also rising ...

Hepatic steatosis steadily increased in patients with HIV and HCV coinfection despite curative treatment with DAA therapy.